Prospective Assessment of Risk Factors for Appropriate ICD Intervention in Patients With Ischemic Cardiomyopathy
The PARCADIA study, sponsored by Biotronik SE & Co. KG, aims to identify predictors for appropriate ICD interventions in patients with ischemic cardiomyopathy. Given the increasing prevalence of heart failure and the associated healthcare costs, this study addresses a significant unmet need in risk stratification for ICD therapy. The findings could enhance patient selection for ICD implantation, potentially improving clinical outcomes and reducing unnecessary healthcare expenditures. The competitive landscape includes other companies developing advanced imaging techniques and risk stratification tools, necessitating diligence in assessing market positioning and potential partnerships.
Indication: ICD
Modality: medical device
Target: Relative Infarct Transmurality (RIT) as assessed by Late Gadolinium Enhanced Cardiac Magnetic Resonance (LGE-CMR) imaging in patients with ischemic cardiomyopathy.
Sponsor: Biotronik SE & Co. KG
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Relative Infarct Transmurality (RIT) as assessed by Late Gadolinium Enhanced Cardiac Magnetic Resonance (LGE-CMR) imaging in patients with ischemic cardiomyopathy.
View original source fields
Condition raw: ICD, Cardiomyopathy Ischemic, Primary Prevention
Condition normalized: ICD, Cardiomyopathy Ischemic, Primary Prevention
Modality raw: medical device
Modality normalized: medical device
Target raw: Relative Infarct Transmurality (RIT) as assessed by Late Gadolinium Enhanced Cardiac Magnetic Resonance (LGE-CMR) imaging in patients with ischemic cardiomyopathy.
Target normalized: Relative Infarct Transmurality (RIT) as assessed by Late Gadolinium Enhanced Cardiac Magnetic Resonance (LGE-CMR) imaging in patients with ischemic cardiomyopathy.